期刊文献+

卵巢癌治疗后早期复发因素的探讨 被引量:3

Early Recurrent Factors of Ovarian Cancer after Treatment
下载PDF
导出
摘要 背景与目的:卵巢癌易复发,目前对其尚无令人满意的有效治疗方法。本文旨在探讨卵巢癌治疗后早期复发的因素,以降低其复发率。方法:回顾性分析1986年1月至1996年5月在我院住院治疗后1年内复发的卵巢癌患者的临床资料,分别比较其不同的临床分期、病理类型、残瘤灶大小、化疗情况的复发率。统计学分析用X^2检验。结果:373例卵巢癌治疗后1年内复发者82例,复发率为22.0%。Ⅰ~Ⅱ期患者的1年内复发率低于Ⅲ~Ⅳ期患者(2.7% vs.30.3%,P<0.01);未分化腺癌患者的复发率高于其它类型患者;残留灶≥2 cm者的复发率高于<2 cm者(33.8% vs.13.7%,P<0.01)。术前化疗者的1年内复发率低于术前未化疗者(11.0% vs.30.5%,P<0.01);术后化疗1~3疗程者复发率高于4~6疗程及>6疗程者(67.0% vs.7.7%,67.0% vs.7.0%,P<0.01)。结论:卵巢癌治疗后1年内复发大多与临床期别较晚、手术切除不彻底和化疗疗程不足有关。 BACKGROUND & OBJECTIVE: Recurrence of ovarian cancer is an important factor that leads to therapeutic failure. At present, the treatment in ovarian cancer is not sufficiently effective. This study was designed to investigate the factors of early recurrence after treatment in ovarian cancer in order to reduce its recurrence. METHODS: The clinical data of the ovarian cancer patients admitted to Affiliated Hospital of Guangxi Medical University during January 1986 to May 1996 who recurred within one year after treatment were analyzed retrospectively. The recurrent rates were compared according to their different clinical stages, pathological types, and residual volumes of the disease as well as the number of courses of pre and postoperative chemotherapy received. Chi-square test was used for statistic analysis. RESULTS: Eighty-two of 373 cases recurred within one year after treatment; the overall recurrent rate was 22. 0%. The 1-year recurrent rate in stage I - II patients was lower than that in stage III - IV patients (2. 7% versus 30. 3%, P < 0. 01). The recurrent rate in the patients with undifferentiated adenocarcinoma was higher than that with other pathological type. The recurrent rate in the patients with residuals 5=2 cm was higher than that with residuals <2 cm (33. 8% versus 13. 7%, P <0. 01). The recurrent rate in the patients with preoperative chemotherapy was lower than that without it. The recurrent rate in the patients who had received only 1 -3 courses of postoperative chemotherapy was higher than that having received 4 -6 or > 6 courses (67. 0% versus 7. 7%, 67. 0% versus 7. 0% , respectively, P < 0. 01). CONCLUSION: Early (1-year) recurrence in the patients with ovarian cancer seems to be closely related to late stage of the disease, incomplete surgery, and insufficient chemotherapy courses.
出处 《癌症》 SCIE CAS CSCD 北大核心 2003年第11期1201-1203,共3页 Chinese Journal of Cancer
关键词 卵巢癌 治疗 早期复发 影响因素 女性生殖器肿瘤 Ovarian cancer Recurrence Surgery Chemotherapy
  • 相关文献

参考文献9

  • 1连利娟 连利娟 林巧稚.卵巢恶性肿瘤的病情监测[A].连利娟, 林巧稚.妇科肿瘤学[C].北京:人民卫生出版社,2000.410- 429.
  • 2Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis[J]. J Clin Oncol, 2002, 20(5): 1248 - 1259.
  • 3Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study[J]. Gynecol Oncol, 1998, 69:103 - 108.
  • 4Brun JL, Feyler A, Chene G, et al. Long-term results and prognostic factors in patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2000, 78(1 ) : 21 - 27.
  • 5Kuhu W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage lllc ovarian carcinoma[J]. Cancer, 2001, 15: 92(10): 2585-2591.
  • 6Mecluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma[J]. J Clin Patnol, 2002, 55(1): 27-31.
  • 7Ehabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother [ J ]. 2001, 2 ( 1 ) : 109 - 124.
  • 8Papadimitriou CA, Kouroussis C, Moulopoulos LA, et al. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer[J]. Cancer, 2001, 92(7): 1856 - 1863.
  • 9Wang J, Li AJ, Karlan BY. Chemotherapy in epithelial ovarian cancer [ J ]. Curr Womens Health Rep, 2002, 2 ( 1 ) : 20 - 26.

共引文献1

同被引文献24

  • 1柳洲,李子庭,于惠卿.卵巢癌新辅助治疗的疗效观察[J].肿瘤防治杂志,2003,10(12):1305-1306. 被引量:5
  • 2颜笑健,梁立治,曾宗渊,刘继红,袁颂华,魏梅.铂类化疗敏感型卵巢上皮癌复发的影响因素[J].癌症,2005,24(6):751-754. 被引量:14
  • 3连丽娟 林巧稚.妇科肿瘤学[M].北京:人民卫生出版社,2000.356-371.
  • 4[4]Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-aaalysis[J].J Clin Oncol,2002,20(4):1248-1259.
  • 5Balat O. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary[J]. Eur J Gynaecol Oncol, 2004, 25 (2): 195~196
  • 6Shibata K, Kikkawa F, Suzuki Y, et al. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer: survival benefit and prognostic factors[J]. Int J Gynecol Cancer, 2003, 13(3):587~592
  • 7Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma [J]. Gynecol Oncol,2001, 82(2): 532~537
  • 8Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery foradvanced ovarian carcinoma during the platinum era: a meta-analysis [J]. J Clin Oncol, 2002,20(5): 1248~1259
  • 9Kuhn W, Rutke S, Spathe K, et al. Neoadjvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in Intenational Federation of Gynecology and Obstetrics stage Ⅲ c ovarian carcinoma [J]. Cancer, 2001, 92 (10):2585 ~2591
  • 10Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer[J]. Gynecol Oncol, 1991, 42(2): 146~150

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部